InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,648.40
(
1.01%
)
US TECH 100
19,050.40
(
1.19%
)
Dow Jones
41,563.08
(
0.55%
)
Brent Oil
77.00
(
0.00%
)
Bitcoin
58,599.32
(
-0.63%
)
Post# of 253004
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rogerm

Send PM Follow Ignore
Followers 2
Posts 112
Boards Moderated 0
Alias Born 08/04/2005

rogerm

Re: ghmm post# 191190

Tuesday, 05/12/2015 10:12:57 PM

Tuesday, May 12, 2015 10:12:57 PM

Post# of 253004
D-Xyrem proved to be too difficult a target to get QD dosing without AM drowsiness. JAZZ has to have that because Flamel's QD drug is advancing. GLPG is in charge of developing the CF drugs thru P2. GLPG's plan is to combine 2 correctors with 1 potentiator for the 508del indication but that is a bit ambitious since none has passed a P1 yet.
http://www.glpg.com/index.php/randd/alliances/cystic-fibrosis/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up